Chinook Therapeutics (KDNY) Stock Price, News & Analysis

Company Overview

Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase I/II trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases. Chinook Therapeutics, Inc. is headquartered in Seattle, Washington. As of August 11, 2023, Chinook Therapeutics, Inc. operates as a subsidiary of Novartis AG.

Key Stats

• Today's Range: $40.39 to $40.39
• 50-Day Range: $38.66 to $40.39
• 52-Week Range: $18.34 to $40.51
• Volume: N/A
• Average Volume: 1.19 million shs
• Market Capitalization: $2.90 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

KDNY Stock Analysis - Frequently Asked Questions

How were Chinook Therapeutics' earnings last quarter?

Chinook Therapeutics, Inc. (NASDAQ:KDNY) announced its quarterly earnings data on Tuesday, May, 9th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by $0.03. The company's quarterly revenue was down 32.2% compared to the same quarter last year.

When did Chinook Therapeutics' stock split?

Chinook Therapeutics's stock split before market open on Saturday, January 1st 2000. The 5-1 split was announced on Saturday, January 1st 2000. The newly minted shares were distributed to shareholders after the market closes on Friday, October 2nd 2020. An investor that had 100 shares of stock prior to the split would have 500 shares after the split.

What other stocks do shareholders of Chinook Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Chinook Therapeutics investors own include BioSyent (RX) and Continental Resources (CLR).

Company Calendar

• Last Earnings: 5/09/2023
• Today: 9/29/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: NASDAQ:KDNY
• CUSIP: N/A
• CIK: 1435049
• Web: chinooktx.com
• Phone: (206) 485-7241
• Fax: N/A
• Employees: 214
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($3.52)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-187,870,000.00
• Net Margins: -4,199.93%
• Pretax Margin: -4,115.56%
• Return on Equity: -58.28%
• Return on Assets: -44.72%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.82
• Quick Ratio: 5.82

Sales & Book Value

• Annual Sales: $6.13 million
• Price / Sales: 473.15
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.91 per share
• Price / Book: 5.85

Miscellaneous

• Outstanding Shares: 71,810,000
• Free Float: 59,749,000
• Market Cap: $2.90 billion
• Optionable: Optionable
• Beta: 0.34